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Nonsteroidal
Antiinflammatory
Drugs and Group A
Streptococcal
Infection
To the Editor: Factor et al.
recently reported the results of a pop-
ulation-based, case-control study
regarding risk factors for pediatric
invasive group A streptococcal
(GAS) infection (1), noting that the
“new” use of nonsteroidal antiinflam-
matory drugs (NSAIDs), defined as
NSAID use <2 weeks before diagno-
sis, was associated with invasive
GAS infection, whereas self-defined
“regular” NSAID use was not. The
control population consisted of non-
hospitalized, age-matched children
contacted by telephone (1). Although
we endorse the authors’ conclusion
that, “…the measurements of new use
and regular use [of NSAIDs] are too
crude to clearly identify their role as
a risk factor,” a more detailed discus-
sion of their findings and conclusions
is warranted.
Because of their antiinflammatory
effects, NSAIDs have been suspected
of suppressing host immunity during
infection, particularly GAS infection
(2). However, determining a causal
association between NSAID use and
infectious diseases has been problem-
atic, especially when using retrospec-
tive studies (3). The results of such
observational studies often suffer from
protopathic bias, in which drugs are
applied to treat symptoms that are
actually early manifestations of the
outcome of interest (4). Consequently,
rather than being a direct determinant
(i.e., causative risk factor) for invasive
GAS infection, NSAID use could
mark the onset of disease symptoms
(fever, localized pain, and inflamma-
tion). Therefore, because of protopath-
ic bias, the study by Factor et al. had a
substantial chance of identifying an
association between NSAID use and
invasive GAS infection a priori.
Neither the fact that patients in the
study by Factor et al. received
NSAIDs any time during the 2 weeks
before the diagnosis of invasive GAS
infection nor the finding that nonhos-
pitalized children (controls) were
unlikely to have received NSAIDs in
the 2 weeks before their interview
should be surprising. A more informa-
tive case-control study would have
matched case-patients with similar-
aged children who had febrile infec-
tions not caused by GAS infection;
both groups of children would have
been equally likely to have received
analgesic and antipyretic medications.
Furthermore, population-based data
suggest that most patients with inva-
sive GAS infection are hospitalized
(5), so hospital-based controls, rather
than population controls, might have
provided a more appropriate compari-
son group.
Prospective studies have failed to
define a causal link between NSAIDs
and invasive GAS infections (3),
though such studies were not specifi-
cally designed to investigate this rela-
tionship. To best test the hypothesis
that NSAIDs increase the risk for
invasive GAS infection, a random-
ized, prospective trial should be done.
Such a trial is unlikely to take place,
however, because of questionable
ethics and because the sample neces-
sary to detect a significant difference
would be prohibitively large.
Although NSAIDs may neither
alter the risk of developing an invasive
GAS infection nor accelerate an estab-
lished infection, these drugs can molli-
fy the signs and symptoms of strepto-
coccal infection, possibly delaying
appropriate management and treat-
ment (3). However, the potential
adverse consequences of suppressing
clinical indicators of disease severity
(e.g., fever, pain, and inflammation)
with NSAIDs apply to myriad infec-
tious and inflammatory conditions, not
just invasive streptococcal disease.
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